Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …

Biological membranes are tricky to investigate. They are complex in terms of molecular
composition and structure, functional over a wide range of time scales, and characterized by …

Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide
3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize …

Lipid phosphoinositides play fundamental roles in virtually all pathways that control a cell's
decision to grow, move, divide, and die. Because of this, kinases that phosphorylate …

The search is on for effective specific inhibitors for PI3Kα mutants. PI3Kα, a critical lipid
kinase, has two subunits, catalytic and inhibitory. PIK3CA, the gene that encodes the p110α …

At the root of the so-called precision medicine or precision oncology, which is our focus
here, is the hypothesis that cancer treatment would be considerably better if therapies were …

Alpelisib selectively inhibits the p110α catalytic subunit of PI3Kα and is approved for
treatment of breast cancers harboring canonical PIK3CA mutations. In head and neck …

How do Ras isoforms attain oncogenic specificity at the membrane? Oncogenic KRas,
HRas, and NRas (K-Ras, H-Ras, and N-Ras) differentially populate distinct cancers. How …

PI3Ks are a family of lipid kinases that phosphorylate PIP2 to PIP3, to which the downstream
signaling target Akt binds to regulate an array of cellular activities, including cell growth …

The sequence-structure-function paradigm has dominated twentieth century molecular
biology. The paradigm tacitly stipulated that for each sequence there exists a single, well …